Lopinavir
What's New
Last Posted: Mar 10, 2023
- HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.
Lathouwers Erkki, et al. HIV clinical trials 2017 0 (5-6) 196-204 - HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.
Hoppe Anne, et al. Antiviral therapy 2017 0 (2) 191-195 - Individualized Protease Inhibitor Monotherapy: The Role of Pharmacokinetics and Pharmacogenetics in an Aged and Heavily Treated HIV-Infected Patient.
López Aspiroz Elena, et al. Clinical drug investigation 2019 0 (11) 1125-1131 - HIV Drug Efavirenz Inhibits CYP21A2 Activity with Possible Clinical Implications.
Malikova Jana, et al. Hormone research in paediatrics 2019 0 (4) 262-270 - Influence of SLCO1B1 polymorphisms on lopinavir C in Serbian HIV/AIDS patients.
Dragovi? Gordana, et al. British journal of clinical pharmacology 2020 0 (7) 1289-1295 - Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients.
Biswas Mohitosh, et al. Pharmacogenomics 2021 0 (6) 375-381 - Potential polymorphic CYP1A2 and CYP2D6-mediated pharmacokinetic interactions between risperidone or olanzapine and selected drugs intended to treat COVID-19.
Rojas-Macetas Ariana, et al. Drug metabolism and bioanalysis letters 2022 0 - Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting.
van Zyl Gert Uves, et al. Journal of acquired immune deficiency syndromes (1999) 2011 0 (4) 333-9 - HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.
Hartkoorn Ruben C, et al. Pharmacogenetics and genomics 2010 0 (2) 112-20 - Pharmacogenomics of COVID-19 therapies.
Takahashi Takuto et al. NPJ genomic medicine 2020 Aug 5(1) 35
More
About PGx PHGKB
PGx PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to medications....more
Content Summary
Common PGx Related Topics
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 21, 2024
- Content source: